Proportion of participants cleared or almost cleared ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants achieving a 50% reduction in disease severity · chronic palmoplantar pustulosis
Ustekinumab showed no clear difference in proportion of participants achieving a 50% reduction in disease… compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ustekinumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in ustekinumab compared with placebo (moderate certainty).
2 findings from 1 review